Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study.

CNS Spectr · 2025 · PMC13064687 · PMID 41117366

Europe PMC DOI

hedged sentence

0.0781

closest p · 1.6× alpha

0.0781

boldest claim

The sentences

a statistical trendp = 0.0781so close (0.05 < p ≤ 0.1)

Effects of 6-month esketamine treatment on neurofilament serum levels As shown in Figure 3 , Wilcoxon signed-rank test showed a statistical trend toward lower sNfL levels after 6 months of treatment with esketamine (14.67 ± 1.64 versus 12.14 ± 1.51, p = 0.0781).

also in 942 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.